Who We Are

Shanghai Shenlian Biomedical Corporation, established in June 2001 with a registered capital of 410.64 million RMB, is a high-tech enterprise specializing in the research, development,production, and sales of veterinary biological products. The headquarter is based in Shanghai.

In October 2019, the company was successfully listed on the Shanghai Stock Exchange's STAR Market with the stock code 688098.

The company's main business covers the research, production, and sales of veterinary preventive biological products and veterinary diagnostic products. It has two GMP production facilities in Shanghai and Lanzhou and is a designated enterprise for foot-and-mouth disease (FMD) vaccines by the Chinese Ministry of Agriculture and Rural Affairs.

Financial strength: + 230 Million USD
Tax contributions: +70 Million USD
Sales Revenue: +42 Million USD
R&D investment: +67 Million USD
Market leadership: + 4 Billion Doses for FMD
Veterinary Vaccine: +9 products
IPO achievement: 1 st animal health company to list on the STAR Market
Certification: GMP, BSL-3,GCP,CNAS
Technical strength: Top-tier player
2001
Established
4 Billion Doses
Market leadership
$ 230 Million
Financial strength

Products & Service

More

Swine Foot and Mouth Disease Type O Synthetic Peptide Vaccine

Contains the foot-and-mouth disease virus (FMDV) of Type O viruses synthetic peptide 2600,2700 and 2800 not less than 25μg/ml, respectively.
More Detail

Swine FMD

Contains the inactivated foot-and-mouth disease virus (FMDV) Strain Re-O/MYA98/JSCZ/2013 and Strain Re‒A/WH/09. Each dose of the vaccine should contain a total 146S content of Type O and Type A viruses no less than 3.0μg, and the content of each virus type should not be less than 1.5μg.
More Detail

Lumpy skin disease

The vaccine contains inactivated AV41 strains of Goatpox virus. The virus titer before inactivation is 106.2TCID50 per milliliter.
More Detail

News

More

Shenlian Biomedical Engages in Strategic Dialogue with African Veterinary Association to Strengthen China-Africa Community with a Shared Future in Livestock Industry

In a significant step towards enhancing the All-Weather China-Africa Community with a Shared Future, Shanghai Shenlian Biomedical Co., Ltd. (Stock Code: 688098), a leading national high-tech enterprise in veterinary biological products, welcomed Dr. Mohamed Faouzi Kechrid, President of the African Veterinary Association, to its facilities.
2024.10.23
More Detail

Shenlian Biomedical has reached a new milestone with the successful completion of the GMP audit

Shanghai Shen Lian Biomedical Corporation Lanzhou Branch is pleased to announce that it has successfully passed the veterinary drug GMP audit and has been granted both the Veterinary Drug GMP Certificate and the Veterinary Drug Production License by the Gansu Provincial Animal Husbandry and Veterinary Bureau.
2024.10.23
More Detail
MSG